Navigation Links
For Treating Clostridium difficile Infections, Surveyed Infectious Disease Specialists Agree That Effect on Recurrence Rate is One of the Drug Attributes that Most Influences Their Prescribing Decisions
Date:4/30/2013

BURLINGTON, Mass., April 30, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed U.S. and European infectious disease specialists agree that effect on recurrence rate is one of the drug attributes that most influences their prescribing decisions when treating Clostridium difficile infections (CDIs). Similarly, surveyed hospital pharmacy directors indicate a high willingness to grant favorable formulary status to therapies that can demonstrate a decrease in recurrence rates of CDIs. However, even though clinical data and interviewed key opinion leaders indicate that emerging therapies provide a significant advantage over current standard-of-care therapies, marketers will need to be cognizant of price in a CDI market dominated by inexpensive and efficacious alternatives.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

The DecisionBase 2013 report entitled Market Opportunity Awaits Therapies That Provide Low Rates of CDI Recurrences finds that surveyed U.S. infectious disease specialists would prescribe Cubist's surotomycin to 15 percent of their CDI patients, driven mostly by surotomycin's lower rate of CDI recurrence relative to oral vancomycin (ViroPharma's Vancocin; generics). However, Decision Resources forecasts that surotomycin will earn a more-modest patient share of 5 percent, constrained partially by continued uptake of fidaxomicin (Optimer/Cubist's Dificid; Astellas' Dificlir), which has already demonstrated superiority in recurrence rates over oral vancomycin.

"Uptake of surotomycin will likely be constrained, unless it can demonstrate either higher clinical efficacy than Dificid or offer more favorable pricing", said Decision Resources Analyst Maria Ascano Ph.D. "Other factors that will also limit surotomycin's uptake are competition from other emerging therapies like cadazolid (Actelion) and MK-3415A (Merck), generic entry of oral vancomycin capsules, and the continued use of oral preparations of IV vancomycin."

Nevertheless, surveyed hospital pharmacy directors are highly willing to grant favorable formulary inclusion to therapies that provide increased clinical cure rates, particularly in CDI patients that suffer from severe and/or recurrent infections. As a result, market opportunity awaits therapies that can demonstrate higher overall clinical efficacy in patients with difficult-to-treat CDIs.

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or
registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. OncoSec ElectroChemotherapy Demonstrates Potential as Alternative to Surgery for Treating Head and Neck Cancer
2. Retrospective Study Suggests that Stereotactic Ablative Radiotherapy (SABR) Can be a Viable Option for Treating Early-Stage Lung Cancer in Operable as well as Inoperable Patients; Phase III Randomized Trial Now Under Way
3. MicroVention Announces First Patient Enrollment In Clinical Trial To Compare Coiling Technologies For Treating Brain Aneurysms
4. Eaton Scientific Discusses Positive Anecdotal Feedback from Pharmacist Compounding Homatropine for Doctors Treating Patients Experiencing Hot Flash Symptoms in the Beverley Hills and Los Angeles Area.
5. ROX Medical secures financing and achieves key milestones in providing minimally-invasive approach for treating hypertension
6. Avaxia Biologics is Awarded U.S. Patent for Antibody Therapy for Modulating Function of Intestinal Receptors and Methods of Treating Diabetes and Obesity
7. The Growing Cost of Aging: Express Scripts Study Shows Medication Use for Normal Aging Conditions Overtakes Costs of Treating Most Chronic Diseases
8. The Nairobi Hospital in Kenya Commences Treating Cancer with Advanced Radiotherapy Delivery Using Varian Equipment and Software
9. Varian Medical Systems to Showcase Advanced Technologies for Treating Cancer with Image-Guided Radiotherapy and Radiosurgery at JASTRO Meeting in Tokyo, Japan
10. Abattis Participates In Project On A Whole Plant Therapeutic For Treating Malaria And Other Diseases And Reducing Drug Resistance
11. Professional Therapy Associates Study Supports Findings: Physical Therapy Beneficial in Treating Office Workers with Lower Back Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2017)... Sept. 22, 2017 Janssen Biotech, Inc. (Janssen) ... letter from the U.S. Food and Drug Administration (FDA) ... sirukumab for the treatment of moderately to severely active ... clinical data are needed to further evaluate the safety ... active RA. ...
(Date:9/19/2017)... ZirMed Inc ., a recognized leader in cloud-based revenue cycle ... ranked #1 by its users for the seventh consecutive year ... ZirMed was recognized as the top-ranked end-to-end revenue cycle management ... 200 beds and holds one of the longest #1 ranking ... ...
(Date:9/12/2017)... and NEW YORK , Sept. 12, 2017 /PRNewswire/ ... ratings for global supply chains, has published the first annual edition of ... performance of more than 20,400 companies evaluated by EcoVadis, based on Scorecard ... and 2016. ... Global CSR Risk & Performance Index ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... 2017 , ... Dr. Parsa Mohebi, the Los Angeles based ... the newly revamped Cosmetic Town journal section, featuring articles written by ... as Follicular Unit Extraction (FUE). , Dr. Mohebi says “I enjoy ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... Leading pediatric ... peers in Washington, D.C., for the 49th Congress of the International Society of ... Vice President of the Center for Cancer and Blood Disorders at Children’s ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... been named one of Michigan’s 2017 Best and Brightest in Wellness® by Best ... in Wellness® awards program on Friday, Oct. 20 from 7:30 a.m. to 2 ...
(Date:10/12/2017)... ... October 12, 2017 , ... In the United States, single-family ... some states—like New York, New Jersey, Massachusetts, Texas, Virginia, Connecticut, and California—the average ... extremely low property-tax rates, which contributes to the relatively lower cost of living ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... at the University of California Berkeley, and other leading institutions in announcing the ... power of institutions to change the way animals are raised for food. , ...
Breaking Medicine News(10 mins):